Innovation in Deal-Making

Innovation in Deal-Making

  • June 2018 •
  • 78 pages •
  • Report ID: 5779989 •
  • Format: PDF
Overview
In order to continually and effectively compete with its peers, as well as with smaller specialty pharmaceutical companies and biotechnology companies, the top 20 global pharmaceutical peer set turns to deal-making as a means to balance out its internally developed portfolio, and to take advantage of the broader capabilities of partners or takeover targets. Through both alliances and therapeutically driven bolt-on acquisitions, the top 20 companies have in-licensed, co-developed, and acquired important assets to help advance their strategies.
This peer set group of companies has become extremely innovative in its deal-making across the key therapy areas of diabetes, neurology (and more specifically, pain), autoimmune disease, and oncology, with good reason, as these areas are where many large pharmaceutical companies realize the biggest proportion of their revenues, and they also represent the leading indications in the RandD pipeline. Over the past 10 years, the top 20 pharmaceutical firms have incorporated novel ideas and approaches into their deal-making, and based on these trends, it is possible to get some insight into where future deals may be focused or emerging.
The following report, a written adaptation of a presentation, examines deal-making trends in both alliances and bolt-on acquisitions over the 10-year period from 2008 to 2017. Unless otherwise cited, data are derived from Informa’s Medtrack and Strategic Transactions.